<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270175</url>
  </required_header>
  <id_info>
    <org_study_id>19-12021159</org_study_id>
    <nct_id>NCT04270175</nct_id>
  </id_info>
  <brief_title>Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab</brief_title>
  <official_title>Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the hypothesis that in patients with previous daratumumab exposure,&#xD;
      combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher&#xD;
      complete remission (CR) rates in relapsed/refractory amyloidosis than historical&#xD;
      pomalidomide/dexamethasone treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Overall Complete Hematologic Response</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Overall complete hematologic response rate will be defined as percentage of participants who achieve Complete Hematologic Response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median estimate of months that participants have progression free survival</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Median estimate calculated using the Kaplan-Meier methodology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median number of months of participant's overall survival</measure>
    <time_frame>Approximately 8 years</time_frame>
    <description>Overall survival (OS) is measured from the date of enrollment to the date of the participant's death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete Hematologic Response</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic complete response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Hematologic progression</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Measured in months between the date of enrollment and the first efficacy evaluation at which the participant has met the criteria for hematologic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until next treatment therapy</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Measured in months from the date of enrollment to the start date of subsequent treatment for AL amyloidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants for Organ response</measure>
    <time_frame>Approximately 5 years</time_frame>
    <description>Organ response rate (OrRR) for kidney and cardiac is defined as the proportion of baseline organ involved participants who achieve organ response in each corresponding organ. Organ response defined for cardiac: N-terminal brain pronatriuretic peptide (NT-proBNP) response (&gt; 30% and &gt; 300 nanogram per liter [ng/L] decrease in participants with baseline NT-proBNP &gt;= 650 ng/L) or New York Heart Association (NYHA) class response (&gt;= 2 class decrease in participants with baseline NYHA class 3 or 4); for kidney: decrease in proteinuria by &gt;=30% or below 0.5 grams /24 hours without renal progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Very Good Partial Response (VGPR) or better hematologic response rates</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Duration of hematologic VGPR or better response is defined as the time between the date of initial documentation of hematologic VGPR or better response to the date of first documented evidence of hematologic progressive disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Amyloid</condition>
  <condition>AL Amyloidosis</condition>
  <condition>Refractory AL Amyloidosis</condition>
  <arm_group>
    <arm_group_label>daratumumab/pomalidomide/dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pomalidomide:&#xD;
(4mg orally) on days 1-21 of a 28-day cycle&#xD;
Dexamethasone:&#xD;
20mg IV as premedication on days 1, 8, 15, and 22&#xD;
20mg orally the day after daratumumab dosing for cycles 1-2 of induction&#xD;
40mg IV as premedication on days 1 and 15 on daratumumab treatment days&#xD;
40mg orally on non-daratumumab days (8 and 15) for cycles 3-6&#xD;
20mg on day 1 of every cycle as premedication on daratumumab dosing day 1 in maintenance cycles (cycles 7 and beyond)&#xD;
If you are a subject age 70 and older, the dexamethasone dosing will be reduced by 50% at the time of induction.&#xD;
Daratumumab:&#xD;
1800mg sub-cutaneously weekly x8 weeks&#xD;
1800mg sub-cutaneously every 2 weeks during induction (cycles 3-6)&#xD;
1800mg sub-cutaneously every 4 weeks cycles 7 and beyond</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daratumumab</intervention_name>
    <description>Given as 1800mg via injection</description>
    <arm_group_label>daratumumab/pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pomalidomide</intervention_name>
    <description>Given as 4mg oral capsule</description>
    <arm_group_label>daratumumab/pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Given as 20mg or 40 mg IV and 20mg or 40mg oral capsule.</description>
    <arm_group_label>daratumumab/pomalidomide/dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of primary AL amyloidosis of tissue&#xD;
&#xD;
          -  Relapsed and/or refractory AL amyloidosis&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Able to give voluntary written consent&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status and/or other performance status&#xD;
             0, 1, or 2.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥ 1,000/mm3 and platelet count ≥ 75,000/mm3.&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN).&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN.&#xD;
&#xD;
          -  Calculated creatinine clearance ≥ 30 mL/min (see Appendix 11.2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-AL amyloidosis&#xD;
&#xD;
          -  Clinically overt myeloma&#xD;
&#xD;
          -  Prior exposure to non-daratumumab anti-CD38 monoclonal antibodies or pomalidomide.&#xD;
&#xD;
          -  Clinically significant cardiac disease&#xD;
&#xD;
          -  Severe obstructive airway disease&#xD;
&#xD;
          -  Female patients who are lactating or have a positive serum pregnancy test during the&#xD;
             screening period&#xD;
&#xD;
          -  Planned high-dose chemotherapy and autologous stem cell transplantation within 6,&#xD;
             28-day treatment cycles after starting on treatment.&#xD;
&#xD;
          -  Failure to have fully recovered (ie, ≤ Grade 1 toxicity) from the reversible effects&#xD;
             of prior chemotherapy.&#xD;
&#xD;
          -  Major surgery within 14 days before enrollment.&#xD;
&#xD;
          -  Radiotherapy within 14 days before enrollment.&#xD;
&#xD;
          -  Infection requiring systemic intravenous antibiotic therapy or other serious infection&#xD;
             within 14 days before study enrollment. Systemic treatment, within 14 days before the&#xD;
             first dose, with strong CYP3A inducers (rifampin, rifapentine, rifabutin,&#xD;
             carbamazepine, phenytoin, phenobarbital, see Appendix 11.7), or use of Ginkgo biloba&#xD;
             or St. John's wort.&#xD;
&#xD;
          -  Positive for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 2 years before study enrollment or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are&#xD;
             not excluded if they have undergone complete resection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cara Rosenbaum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathleen P Research Nurse Coordinator, RN</last_name>
    <phone>646-962-6500</phone>
    <email>kap9111@med.cornell.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Liedtke, MD</last_name>
      <email>mliedtke@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michaela Liedtke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vaishali Sanchorawala, MD</last_name>
      <email>Vaishali.Sanchorawala@bmc.org</email>
    </contact>
    <investigator>
      <last_name>Vaishali Sanchorawala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine - Multiple Myeloma Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Research Nurse Coordinator</last_name>
      <phone>646-962-6500</phone>
      <email>kap9111@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Research Nurse Coordinator</last_name>
      <phone>(646) 962-6500</phone>
      <email>naa9101@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cara Rosenbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita D'Souza, MD</last_name>
      <email>anitadsouza@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Anita D'Souza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Light-chain Amyloidosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Pomalidomide</mesh_term>
    <mesh_term>Daratumumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

